PDF(1160 KB)
COVID-19疫苗的有效性和安全性的系统评价
邢凯, 涂晓燕, 刘苗, 梁章武, 陈江南, 李姣姣, 江利国, 邢富强, 姜毅
中国当代儿科杂志 ›› 2021, Vol. 23 ›› Issue (3) : 221-228.
PDF(1160 KB)
PDF(1160 KB)
COVID-19疫苗的有效性和安全性的系统评价
Efficacy and safety of COVID-19 vaccines: a systematic review
目的 系统评价新型冠状病毒肺炎（COVID-19）疫苗的有效性和安全性。方法 通过计算机检索有关COVID-19疫苗的临床随机对照试验文献，对临床试验结果进行定性分析。检索时间为各数据库建库至2020年12月31日。所检索的数据库包括PubMed、Embase、Cochrane图书馆、Clinicaltrial.gov、中国知网、万方数据、中国生物医学文献服务系统和中国临床试验注册中心。使用Cochrane偏倚风险评估工具评估文献质量。结果 纳入了13项随机、盲法、对照试验，涉及11种COVID-19疫苗接种的安全性和有效性。在其中10项研究中，受试者的28 d血清转化率超过80%；2项万人规模的临床试验中，分别取得了95%和70.4%的有效率；1项研究的血清转化率低于60%。在对接种后28 d内不良反应发生率的分析显示，6项研究不良反应发生率低于30%，2项研究为30%~50%，2项研究高于50%。在13项研究中，疫苗接种不良反应事件绝大部分为轻度到中度，在接种后24 h内缓解；最常见的局部不良反应为注射部位疼痛或压痛，最常见的系统性不良反应为疲劳、发热或躯体痛。受试者对疫苗的免疫反应和不良反应发生率与接种剂量呈正相关。老年人对疫苗的免疫反应较年轻人差。6项研究比较了疫苗单剂量与双剂量接种的效应，其中4项研究显示双剂量接种比单剂量接种产生更强的免疫反应。结论 大部分COVID-19疫苗具有较好的有效性和安全性；推荐双剂量接种。然而COVID-19疫苗的长期有效性、安全性及剂量、年龄和工艺差异对保护效力的影响需要更多的研究证实。
Objective To evaluate systematically the efficacy and safety of COVID-19 vaccines. Methods PubMed, Embase, Cochrane Library, Clinicaltrial.gov, CNKI, Wanfang Data, China Biomedical Literature Service System, and China Clinical Trial Registry were searched for randomized controlled trials of COVID-19 vaccines published up to December 31, 2020. The Cochrane bias risk assessment tool was used to assess the quality of studies. A qualitative analysis was performed on the results of clinical trials. Results Thirteen randomized, blinded, controlled trials, which involved the safety and efficacy of 11 COVID-19 vaccines, were included. In 10 studies, the 28-day seroconversion rate of subjects exceeded 80%. In two 10 000-scale clinical trials, the vaccines were effective in 95% and 70.4% of the subjects, respectively. The seroconversion rate was lower than 60% in only one study. In six studies, the proportion of subjects who had an adverse reaction within 28 days after vaccination was lower than 30%. This proportion was 30%-50% in two studies and > 50% in the other two studies. Most of the adverse reactions were mild to moderate and resolved within 24 hours after vaccination. The most common local adverse reaction was pain or tenderness at the injection site, and the most common systemic adverse reaction was fatigue, fever, or bodily pain. The immune response and incidence of adverse reactions to the vaccines were positively correlated with the dose given to the subjects. The immune response to the vaccines was worse in the elderly than in the younger population. In 6 studies that compared single-dose and double-dose vaccination, 4 studies showed that double-dose vaccination produced a stronger immune response than single-dose vaccination. Conclusions Most of the COVID-19 vaccines appear to be effective and safe. Double-dose vaccination is recommended. However, more research is needed to investigate the long-term efficacy and safety of the vaccines and the influence of dose, age, and production process on the protective efficacy.
新型冠状病毒肺炎 / 严重急性呼吸综合征冠状病毒2 / 疫苗 / 系统评价 / 有效性 / 安全性 / 临床试验
COVID-19 / SARS-CoV-2 / Vaccine / Systematic review / Efficacy / Safety / Clinical trial
[1] World Health Organization. WHO coronavirus disease (COVID-19) dashboard[EB/OL]. (2021-02-15)[2021-02-16]. https://covid19.who.int/.
[2] Sun JM, He WT, Wang LF, et al. COVID-19:epidemiology, evolution, and cross-disciplinary perspectives[J]. Trends Mol Med, 2020, 26(5):483-495.
[3] 习近平. 在全国抗击新冠肺炎疫情表彰大会上的讲话(2020年9月8日)[J]. 求是, 2020(20):4-15.
[4] Zhu N, Zhang DY, Wang WL, et al. A novel coronavirus from patients with pneumonia in China, 2019[J]. N Engl J Med, 2020, 382(8):727-733.
[5] 中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第八版)[J]. 中华临床感染病杂志, 2020, 13(5):321-328.
[6] Oliveira BA, Oliveira LC, Sabino EC, et al. SARS-CoV-2 and the COVID-19 disease:a mini review on diagnostic methods[J]. Rev Inst Med Trop Sao Paulo, 2020, 62:e44.
[7] Wang J, Pan LJ, Tang S, et al. Mask use during COVID-19:a risk adjusted strategy[J]. Environ Pollut, 2020, 266(Pt 1):115099.
[8] Li T, Liu Y, Li M, et al. Mask or no mask for COVID-19:a public health and market study[J]. PLoS One, 2020, 15(8):e0237691.
[9] 中华人民共和国国家卫生健康委员会办公厅. 医疗机构内新型冠状病毒感染预防与控制技术指南(第一版)[J]. 中国感染控制杂志, 2020, 19(2):189-191.
[10] Cao YC, Deng QX, Dai SX. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19:an evaluation of the evidence[J]. Travel Med Infect Dis, 2020, 35:101647.
[11] Pardo J, Shukla AM, Chamarthi G, et al. The journey of Remdesivir:from Ebola to COVID-19[J]. Drugs Context, 2020, 9:2020-2024.
[12] Tirupathi R, Bharathidasan K, Palabindala V, et al. Comprehensive review of mask utility and challenges during the COVID-19 pandemic[J]. Infez Med, 2020, 28(Suppl 1):57-63.
[13] Provenzani A, Polidori P. COVID-19 and drug therapy, what we learned[J]. Int J Clin Pharm, 2020, 42(3):833-836.
[14] Romero JR, Bernstein HH. COVID-19 vaccines:a primer for clinicians[J]. Pediatr Ann, 2020, 49(12):e532-e536.
[15] Sharma O, Sultan AA, Ding H, et al. A review of the progress and challenges of developing a vaccine for COVID-19[J]. Front Immunol, 2020, 11:585354.
[16] Korang SK, Juul S, Nielsen EE, et al. Vaccines to prevent COVID-19:a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project)[J]. Syst Rev, 2020, 9(1):262.
[17] Wang JL, Peng Y, Xu HY, et al. The COVID-19 vaccine race:challenges and opportunities in vaccine formulation[J]. AAPS PharmSciTech, 2020, 21(6):225.
[18] Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002):a single-blind, randomised, controlled, phase 2/3 trial[J]. Lancet, 2021, 396(10267):1979-1993.
[19] Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2:an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK[J]. Lancet, 2021, 397(10269):99-111.
[20] Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine[J]. N Engl J Med, 2020, 383(27):2603-2615.
[21] Xia SL, Duan K, Zhang YT, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes:interim analysis of 2 randomized clinical trials[J]. JAMA, 2020, 324(10):951-960.
[22] Pu J, Yu Q, Yin ZF, et al. An in-depth investigation of the safety and immunogenicity of an inactivated SARS-CoV-2 vaccine[J]. medRxiv, 2020. DOI:10.1101/2020.09.27.20189548. Epub ahead of print.
[23] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses:the PRISMA statement[J]. PLoS Med, 2009, 6(7):e1000097.
[24] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions:explanation and elaboration[J]. Ann Intern Med, 2009, 151(4):W65-W94.
[25] Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions[M]. 2nd ed. Chichester, UK:John Wiley & Sons, 2019.
[26] Cumpston M, Li TJ, Page MJ, et al. Updated guidance for trusted systematic reviews:a new edition of the Cochrane Handbook for Systematic Reviews of Interventions[J]. Cochrane Database Syst Rev, 2019, 10:ED000142.
[27] Xia SL, Zhang YT, Wang YX, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV:a randomised, double-blind, placebo-controlled, phase 1/2 trial[J]. Lancet Infect Dis, 2021, 21(1):39-51.
[28] Che YC, Liu XQ, Pu Y, et al. Randomized, double-blinded, placebo-controlled phase 2 trial of an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in healthy adults[J]. Clin Infect Dis, 2020. DOI:10.1093/cid/ciaa1703. Epub ahead of print.
[29] Ella R, Vadrevu KM, Jogdand H, et al. A phase 1:safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152[J]. medRxiv, 2020. DOI:10.1101/2020.12.11.20210419. Epub ahead of print.
[30] Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine[J]. N Engl J Med, 2020, 383(24):2320-2332.
[31] Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/Ⅱ study of COVID-19 RNA vaccine BNT162b1 in adults[J]. Nature, 2020, 586(7830):589-593.
[32] Richmond P, Hatchuel L, Dong M, et al. A first-in-human evaluation of the safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19 in healthy adults; a phase 1, randomised, double-blind, placebo-controlled trial[J]. medRxiv, 2020. DOI:10.1101/2020.12.03.20243709. Epub ahead of print.
[33] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates[J]. N Engl J Med, 2020, 383(25):2439-2450.
[34] Zhang YJ, Zeng G, Pan HX, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years:a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial[J]. Lancet Infect Dis, 2021, 21(2):181-192.
[35] Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older:a randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2020, 396(10249):479-488.
[36] Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults[J]. N Engl J Med, 2020, 383(25):2427-2438.
[37] Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations:two open, non-randomised phase 1/2 studies from Russia[J]. Lancet, 2020, 396(10255):887-897.
中央高校基本科研业务费专项资金资助项目（2042020kf1011）。
